Murine IL-10 fails to reduce GVHD despite inhibition of alloreactivity in vitro

Bone Marrow Transplantation

Volumn 18, Issue 2, 1996, Pages 369-375

  Emmanouilides, C E ^a   Luo, J ^a   Baldwin, G ^a   Buckley, D ^a   Lau, P ^a   Lopez, E ^a   Tabibzadeh, S ^a   Yu, J ^a   Wolin, M ^a   Rigor, R ^a   Territo, M ^a   Black, A C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AKR mice; B10.BR mice; Graft versus host disease; Interleukin 1 ; Interleukin 10; Marrow transplantation

Indexed keywords

CYTOKINE; INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 10;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE FUNCTION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; INTERLEUKIN-1; INTERLEUKIN-10; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED AKR; MICE, INBRED C57BL; RECOMBINANT PROTEINS;

EID: 9444233862     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bortin MM, Horowitz MM, Rimm AA. Progress report from the International BMT Registry. Bone Marrow Transplant 1992; 10: 113-122.
2. Vogelsang GB, Hess AD, Santos GW. Acute graft-versus-host disease: clinical characteristics in the cyclosporine era. Medicine 1988; 67: 163-174.
3. Ferrara JLM, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991; 324: 667-674.
4. Ferrara JLM. Cytokine dysregulation as a mechanism of graft-versus-host disease. Curr Opin Immunol 1993; 5: 794-799.
5. Nierle T, Bunjes D, Arnold R et al. Quantitative assessment of post-transplant host-specific IL-2 secreting T-helper cell precursors in patients with and without acute graft-versus-host disease after allogeneic HLA-identical sibling bone marrow transplantation. Blood 1993; 81: 841-848.
6. Theobald M, Buynes D, Nierle T et al. Measurement of recipient specific alloreactivity: is GVHD predictable? Bone Marrow Transplant 1993; 12 (Suppl. 3): 5018-5023.
7. Holler E, Kolb HJ, Hintemeier-Knabe R et al. Role of tumor necrosis factor-alpha in acute GVHD and complications following allogeneic bone marrow transplantation. Transplant Proc 1993; 25: 1234-1236.
8. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
9. Ferrera JLM, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for IL-1. Transplant Proc 1993; 25: 1216-1217.
10. Oluwole SJ, Engelstad K, James T. Prevention of graft-versus-host disease and bone marrow rejection: kinetics of induction of tolerance by UVB modulation of accessory cells and T cells in the bone marrow inoculum. Blood 1993; 81: 1658-1665.
11. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin-10. J Exp Med 1991; 174: 1549-1555.
12. Bentel J, Atkinson K. Cytokine activity after human bone marrow transplantation. Br J Haematol 1988; 69: 181-187.
13. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse helper T-cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081-2095.
14. Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451.
15. de Waal Malefyt R, Abrams J, Bennett B et al. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.
16. Moore KW, O'Garra A, de Waal Malefyt R et al. Interleukin-10. Ann Rev Immunol 1993; 11: 165-190.
17. Ding L, Linsley PS, Huang LY et al. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224-1234.
18. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T-cells. Science 1992; 258: 1156-1159.
19. de Waal Malefyt R, Yssel H, deVries JE. Direct effects of IL-10 on subsets of human CD4+ T-cell clones and resting T-cells; specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150: 4754-4765.
20. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81: 2964-2971.
21. Howard M, Muchamuel T, Andrade S et al. Inlerleukin-10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205-1208.
22. Gerard C, Bruyns C, Marachant A et al. Interleukin-10 reduces the rate of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177: 547-550.
23. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen presenting function by IL-10 - a role for IL-10 in induction of tolerance. J Immunol 1993; 151: 2390-2396.
24. Bacchetta R, Bigler M, Touraine JL et al. High levels of interleukin-10 production in vivo are associated with tolerance in SClD patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179: 493-502.
25. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T-cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991; 77: 2515-2523.
26. Drobynski KW, Keever CA, Hanson GA et al. Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival and impaired alloengraftment in mice undergoing GVHD after bone marrow transplantation. Blood 1994; 84: 2363-2373.
27. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after BMT breaks graft-versus-host tolerance and allows for persistent antileukemic reactivity without severe GVHD. Blood 1995; 85: 3302-3312.
28. Sykes M, Harty MW, Pearson DA. Strain dependence of IL-2 induced GVHD protection: evidence that IL-2 inhibits selected CD4 functions. J Immunother 1994; 15: 11-21.
29. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine GVHD. Blood 1995; 86: 2424-2438.
30. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor marrow grafts. Blood 1995; 85: 842-851.
31. Kregner W, Snyder K, Smith S, Ferrara J. Effect of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 1994; 58: 1251-1257.
32. Rowbottom AW, Riches PG, Downie C, Hobbs JR. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 635-641.
33. Wall DA, Sheehan KCF. The role of TNF and IFN-g in GVHD and related immunodeficiency. Transplantation 1994; 57: 273-279.
34. Brok HPMH, Heidt PJ, van der Meide PH et al. Interferon gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451-6459.
35. Sykes M, Romick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin-2 plus T-cell depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med 1990; 171: 645-658.
36. Berger M, Wettstein PJ, Korngold R. T cell subsets in lethal GVHD directed to immunodominant minor histocompatibility antigens. Transplantation 1994; 57: 1095-1102.
37. Sprent J, Schaefer M, Korngold R. Role of T cell subsets in lethal GVHD directed to class I versus class II H-2 differences. Protective effect of L3T4+ cells in anti-class II GVHD. J Immunol 1990; 144: 2946-2954.
38. DeGast GC, Mickelson EM, Beatty PC et al. Mixed leukocyte culture reactivity and graft-versus-host disease in HLA identical marrow transplantation for leukemia. Bone Marrow Transplant 1992; 9: 87-90.